DKF-340 is under clinical development by Dongkook Pharmaceutical and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DKF-340’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DKF-340 overview
DKF-340 is under development for the treatment of inflammation. It is an improved formulation of an NSAID drug.
Dongkook Pharmaceutical overview
Dongkook Pharmaceutical (Dongkook) is a pharmaceutical company. It develops, manufactures and distributes pharmaceutical products, healthcare products and medical devices. Its offers products that include generic drugs, quasi-drugs, prescription-based drugs, medical devices and active pharmaceutical ingredients. It provides products under the brands Insadol Plus, Madecassol, Feramine Q, Sencia, Pansidil, Chisen, Karitopoten, Oramedi and others. It operates a factory located in Jincheon-gun, South Korea. Dongkook is headquartered in Gangnam-gu, Seoul, South Korea.
For a complete picture of DKF-340’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
